Braidwell LP Buys 241,100 Shares of Boston Scientific Corporation $BSX

Braidwell LP grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 69.6% during the 2nd quarter, Holdings Channel reports. The firm owned 587,567 shares of the medical equipment provider’s stock after buying an additional 241,100 shares during the period. Braidwell LP’s holdings in Boston Scientific were worth $25,077,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $25,000. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter worth $26,000. Swiss RE Ltd. bought a new stake in Boston Scientific during the fourth quarter worth $26,000. Garton & Associates Financial Advisors LLC bought a new stake in Boston Scientific during the fourth quarter worth $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new stake in Boston Scientific in the first quarter valued at $28,000. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on BSX. Piper Sandler reissued an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a research report on Friday, June 12th. Truist Financial dropped their target price on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Barclays cut their target price on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research note on Thursday, May 28th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Finally, Wells Fargo & Company dropped their price objective on Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $48.40 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The firm has a market cap of $70.14 billion, a price-to-earnings ratio of 19.59, a P/E/G ratio of 1.11 and a beta of 0.57. The stock’s fifty day moving average price is $46.77 and its two-hundred day moving average price is $55.99. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the business posted $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has authorized a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney bought 186,240 shares of the stock in a transaction dated Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 194,522 shares of company stock worth $9,385,210 in the last quarter. 0.34% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.